2
April 2024
Oncimmune Holdings plc
("Oncimmune" or the
"Company")
Total Voting Rights
Oncimmune Holdings plc (AIM: ONC.L),
a leading autoantibody profiling company to the pharmaceutical and
biotechnology industry enabling precision medicine, announces that
as at 31 March 2024 the Company's issued share capital
consisted of 74,142,147 ordinary shares each carrying one
voting right. The Company does not hold any ordinary shares
in treasury. Therefore, the total number of voting rights in
the Company as at 31 March 2024 was 74,142,147.
The above figure
of 74,142,147 may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, Oncimmune under the Financial Conduct
Authority's Disclosure Guidance and Transparency Rules.
For further
information:
Oncimmune
Holdings plc
contact@oncimmune.com
Singer Capital Markets (Nominated
Adviser and Broker)
Philip Davies, Harry Gooden, James
Fischer
+44 (0)20 7496 3000
Zeus (Joint Broker)
Dominic King, Victoria Ayton, Dan
Bate
+44 (0)20 3829 5000
+44 (0)20 3727 1000
About Oncimmune
Oncimmune is a precision medicine
company, specialising in analysing immune interactions through the
autoantibody profile. Taking a platform approach to generating
insights, Oncimmune is partnering with global pharmaceutical and
biotech companies, as well as contract research organisations
(CROs) to discover novel biomarkers for the development of more
targeted and effective therapies across many immune-mediated
diseases. Our mission at Oncimmune is to enable precision medicine.
We help our partners to discover novel biomarkers, drug targets and
predict treatment efficacy through the application of our platform.
We are able to do this by deploying our world class scientific team
and our cutting-edge technology platform, built on years of
experience in the field. Our aim is to make this an essential tool
in drug discovery and development.
Oncimmune is headquartered in the UK,
with its discovery and development facility based in Dortmund,
Germany and a business development team based in the US and
Europe.
For more information,
visit www.oncimmune.com
